{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:50:36Z","timestamp":1755798636772,"version":"3.44.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Acute severe ulcerative colitis (ASUC) is a life-threatening condition in patients with ulcerative colitis with overwhelming systemic inflammation. In case of steroid-refractory courses, the mainstay of therapy is currently infliximab or a calcineurin inhibitor, weighed against colectomy. Recently, Janus kinase (JAK) inhibitors have been shown to result in rapid and persistent responses even in steroid-refractory patients, so that their position in the therapeutic algorithm of ASUC has to be determined. We present\u2014to our best knowledge, for the first time\u2014two cases in which upadacitinib was administered as a third-line rescue therapy in steroid- and infliximab-refractory patients with persistent fever.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentations<\/jats:title><jats:p>A 33- and a 28-year-old man, both newly diagnosed with ulcerative pancolitis, presented with steroid-refractory courses of ASUC. Both suffered from fever with temperatures of &amp;gt;39\u00b0C in spite of empirical antibiotic therapy, and infection was carefully excluded. In both, infliximab at 5 mg\/kg body weight failed to resolve the fever, and second salvage therapy with upadacitinib 45 mg led to swift resolution of the fever and to overall clinical response. Both patients were under ongoing upadacitinib treatment, and in outpatient surveillance, one of them in steroid-free clinical remission up to his last follow-up one year post treatment initiation, the other one up to his last follow-up four months post treatment initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Upadacitinib seems to be a valuable option even as a second salvage therapy in ASUC. Randomized controlled trials are warranted. However, it has to be kept in mind that ASUC, especially with septic symptoms such as fever, remains a life-threatening condition in which surgery always has to be evaluated, and that multiple overlapping immunosuppressive therapies may cause severe complications, such as infections.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fgstr.2025.1626455","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:41:07Z","timestamp":1755600067000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Rapid resolution of fever after initiation of third-line rescue treatment with upadacitinib for acute severe ulcerative colitis in two young men"],"prefix":"10.3389","volume":"4","author":[{"given":"Dan","family":"Pinzaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kreysing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Lesmeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Schwandner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Michl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Gauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac104","article-title":"European crohn\u2019s and colitis organisation [ECCO]. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"Truelove","year":"1954","journal-title":"Br Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00016-9","article-title":"Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study","volume":"6","author":"Sebastian","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf013","article-title":"Tofacitinib for hospitalized acute severe ulcerative colitis management (The TRIUMPH study)","volume":"7","author":"Narula","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: A systematic review","volume":"31","author":"Damianos","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib salvage therapy for infliximab-experienced patients with acute severe ulcerative colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: A multicenter experience","volume":"27","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542711","article-title":"Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: A case report","volume":"19","author":"Huynh","year":"2024","journal-title":"Case Rep Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251323511","article-title":"Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series","volume":"18","author":"Etchegaray","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.04.035","article-title":"Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis","volume":"6","author":"Maser","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three janus kinase inhibitors in ulcerative colitis: A real-world multicentre study in Japan","volume":"61","author":"Akiyama","year":"2025","journal-title":"Aliment. Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1128\/CMR.15.1.79-94.2002","article-title":"Clinical aspects and pathophysiology of inflammatory bowel disease","volume":"15","author":"Hendrickson","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/317513","article-title":"Circulating cytokines as mediators of fever","author":"Netea","year":"2000","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2025.1626455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:41:07Z","timestamp":1755600067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2025.1626455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":25,"alternative-id":["10.3389\/fgstr.2025.1626455"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2025.1626455","relation":{},"ISSN":["2813-1169"],"issn-type":[{"type":"electronic","value":"2813-1169"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"1626455"}}